ENDOVAC has potential to dramatically improve survival of patients with life-threatening infection following a leak from their the upper gastrointestinal tract
Medovate has secured the exclusive rights to bring to market a pioneering new endoscopic surgical device.
The new device, ENDOVAC, has the potential to dramatically improve survival of patients with life-threatening infection following a leak from their the upper gastrointestinal (GI) tract while significantly enhancing current treatment methods.
Developed by a team led by Mr Andrew Hindmarsh, consultant oesophagogastric surgeon at Cambridge University Hospitals NHS Foundation Trust; ENDOVAC is also backed by a £1.2m grant from the National Institute for Health Research, which has a number of regional specialist partners including the hospital, the Cambridge Clinical Trials Unit, Health Enterprise East, and Suffolk-based JEB Technologies.
Medovate’s role is to attain regulatory approval and commercialise this technology, with a view to beginning clinical evaluation as early as 2021 and market launch thereafter.
Each year, around 2,800 people in the UK get a hole in their upper GI tract. These may occur on their own; arise from problems such as stomach ulcers; or be caused through surgery or other medical interventions.
The presence of a hole allows leakage of gastrointestinal contents into the body which quickly leads to infection around vital organs such as the heart and lungs, a serious medical emergency that is fatal if not treated successfully.
In the past, the standard treatment for these holes has been surgery, but this was often unsuccessful.
So, more recently, surgeons have developed an alternative treatment strategy for this problem called Endoluminal Vacuum Therapy (EVT).
The team at Cambridge University Hospitals NHS Foundation Trust has come up with a straightforward-yet-effective device that presents a compelling proposition in terms of both patient outcomes and potentially-significant cost savings to the NHS
However, this treatment still needs improvement as it requires multiple technically-difficult procedures under general anaesthesia in an operating theatre to be successful.
ENDOVAC marks a ground-breaking progression of EVT.
The technology allows easier delivery of treatment without the need for general anaesthesia, meaning the procedure does not need to be performed in an operating theatre.
It makes EVT safer, quicker, easier and cheaper, and, importantly, far less traumatic for patients.
It will also enable patients to be mobile during treatment, unlike standard EVT, where patients are often confined to their hospital beds.
Robert Donald, new business manager at Medovate, said: “ENDOVAC offers a deceptively-simple solution to a complex problem that has sadly claimed many lives over the years.
“The team at Cambridge University Hospitals NHS Foundation Trust has come up with a straightforward-yet-effective device that presents a compelling proposition in terms of both patient outcomes and potentially-significant cost savings to the NHS.
“ENDOVAC is a natural addition to the Medovate portfolio of innovations in the fields of surgery, anaesthesia and intensive care and we fully expect to see ENDOVAC in use in our hospitals in the not-too-distant future.”